Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
about
START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus InfectionChronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistenceWhen to start antiretroviral therapy: as soon as possibleHIV and aging: emerging research issuesMarkers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patientsInnate immune responses and rapid control of inflammation in African green monkeys treated or not with interferon-alpha during primary SIVagm infectionSoluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort studyThe clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefitA randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adultsAssociation of low level viremia with inflammation and mortality in HIV-infected adultsCardiovascular Complications of HIV in Endemic Countries.Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV InfectionAtherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.HIV Infection and Acute Stroke: A Case Report and a Review of the Literature.HIV-associated changes in the enteric microbial community: potential role in loss of homeostasis and development of systemic inflammationEvaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.Systemic effects of inflammation on health during chronic HIV infectionCoagulation and morbidity in treated HIV infection.Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected AdultsVirological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.Inflammatory cytokines and mortality in a cohort of HIV-infected adults with alcohol problems.Empiric deworming and CD4 count recovery in HIV-infected Ugandans initiating antiretroviral therapy.Residual immune dysregulation syndrome in treated HIV infection.Association between systemic inflammation and obstructive sleep apnea in men with or at risk for HIV infectionInflammatory cytokines drive CD4+ T-cell cycling and impaired responsiveness to interleukin 7: implications for immune failure in HIV disease.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.Biomarkers and HIV-associated cardiovascular disease.Chronic HIV disease and activation of the coagulation systemHIV-1 infection is associated with changes in nuclear receptor transcriptome, pro-inflammatory and lipid profile of monocytes.Excess soluble CD40L contributes to blood brain barrier permeability in vivo: implications for HIV-associated neurocognitive disordersElevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort.HIV, dementia and antiretroviral drugs: 30 years of an epidemic.Immunologic basis of cardiovascular disease in HIV-infected adults.Immune dysregulation and vascular risk in HIV-infected patients: implications for clinical care.Cardiovascular implications from untreated human immunodeficiency virus infection.Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial
P2860
Q26753830-6F6B890E-15A7-44F2-B64B-F0201041358BQ26825762-72408587-5733-4E11-8AE2-0C7A5E383CBDQ27006767-2F663D24-D5E0-4B43-BF93-5E5297871F72Q27016011-8B515B70-DBE8-4D41-BFEF-48C44FB2FD06Q27024262-E391693C-8C95-4969-8B59-640043237A3BQ27324621-6DCDFEC6-803B-4AA9-AA1C-10807F1DB478Q27690715-34FF547E-F494-4BDE-A3DB-EA505B9A4608Q28484274-D6797AD3-FCE6-476B-A586-6E19931C92C3Q28535156-DBD08965-BFB4-4628-AB20-E073C521FC9AQ28740565-3F6CACB4-EA70-4308-B6E7-BD99B00A15F4Q28743237-4FF3392E-EBE6-4886-A19C-A7199436D339Q30244655-92DC6BEC-5F9D-4CF6-BBC1-D4AF4B211497Q30245379-1C2176CB-5A88-4E2A-B99B-A3AF82D12E26Q30248286-D2A556BD-C209-429C-A1EE-3189B4D1E03FQ30670446-34014064-EC47-4909-8C0C-14099F1D15D1Q30839904-1E668DC1-5DFF-4693-8DF7-EDB8FF0C8E1FQ31118978-E5406822-F0FA-47B7-9BB2-A625117C1AE2Q33577551-166C4933-3E43-4CBD-AE63-9DE43A79D5D0Q33614424-30A28984-E1E6-4000-879A-B05036D2A4B1Q33813894-597095D8-6EBF-4AC8-8E74-FD05BE96C2A1Q33880782-EB84D6E7-C70E-4656-A13C-D9D978058B2BQ33917180-FC8A09E9-743A-45A1-AFA2-05AECD9172C8Q33926735-FF7126BC-C393-4D0C-9442-5FEA5738E2BCQ34016057-A3218F63-DD42-4786-AFA1-9052A3C1ABABQ34020121-9F4108A4-B9AE-4786-A497-3242A13512F6Q34036498-1AAA4D02-8282-4534-B955-C3E56894B460Q34229695-99779DC4-BF57-46CD-A75F-125EA82F20BCQ34315572-00E0902F-B4A5-49D0-9593-132F128D7EEFQ34315579-90055330-9EAE-4905-AE12-E4EA8DC67723Q34335486-6C58F875-C2BD-46B0-B749-0DA38AEEA9E1Q34342368-FC313A9F-8D6C-4F19-9D04-CC8B43C41EA4Q34459345-41D4667B-9974-4D0D-8ED1-71B8AC3D10C1Q34517239-2B8FF90C-9958-4DED-9E7A-54F0E5D9F344Q34553819-338EC530-C27F-4C59-B00B-EBFFABB5F111Q34573511-0AA35A51-8796-48C5-B207-73C85604EB28Q34638205-6930B765-B8D0-411A-9145-86D3BD94E530Q34764372-94D47989-FF4B-4338-A4B9-BF3611C81654Q34793193-C4C80A95-7FA6-4F0F-80C1-D0C855810086Q34796153-2C603829-E1E7-4870-9787-CD7FC36BF370Q34818798-2E498C17-4873-4B20-8FF8-D9AE625D5CAA
P2860
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@ast
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@en
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@nl
type
label
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@ast
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@en
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@nl
prefLabel
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@ast
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@en
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@nl
P2093
P2860
P1476
Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort.
@en
P2093
Andrew R Zolopa
Andy I Choi
Carl Grunfeld
Constance Benson
Peter Bacchetti
Phyllis C Tien
Rebecca Scherzer
Russell Tracy
P2860
P304
P356
10.1097/QAI.0B013E3181E66216
P407
P577
2010-11-01T00:00:00Z